ORCHPHARMA

Orchid Pharma Limited

Orchid Pharma Limited (ORCHPHARMA) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

orchidpharma.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹911.25
Market cap
5,441 Cr
Stock P/E
627.8
P/B
3.59
ROE (FY26)
1.6%
ROCE (FY26)
2.0%
Operating margin (FY26)
0.7%
Debt / equity (FY26)
0.28
OCF / EBITDA (FY26)
246.0%
OCF / EBITDA (3Y)
91.6%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Orchid Pharma makes cephalosporin antibiotic ingredients (active pharmaceutical ingredients, or APIs) and antibiotic formulations at its plant in Alathur, Tamil Nadu, selling mostly to export customers.

Company snapshot

59thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓92% of operating profit came in as cash over the last three years — profits are backed by real cash.
Concerns
  • ✗Net margin is very thin at 2.5% — little room for error if costs rise.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales199 Cr221 Cr217 Cr244 Cr223 Cr217 Cr237 Cr173 Cr194 Cr207 Cr238 Cr304 Cr
Operating expenses (approx.)175 Cr185 Cr188 Cr212 Cr192 Cr191 Cr209 Cr159 Cr195 Cr206 Cr211 Cr290 Cr
EBITDA23 Cr35 Cr29 Cr32 Cr30 Cr26 Cr28 Cr14 Cr-1 Cr2 Cr27 Cr14 Cr
OPM %11.7%16.0%13.3%13.3%13.6%12.1%11.8%8.2%-0.8%0.8%11.3%4.6%
Other income8 Cr8 Cr13 Cr8 Cr8 Cr8 Cr4 Cr11 Cr11 Cr6 Cr7 Cr2 Cr
Interest4 Cr4 Cr3 Cr3 Cr3 Cr4 Cr4 Cr3 Cr4 Cr3 Cr3 Cr2 Cr
Depreciation8 Cr9 Cr8 Cr8 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr11 Cr
Profit before tax20 Cr29 Cr30 Cr29 Cr27 Cr21 Cr22 Cr15 Cr-6 Cr-13 Cr24 Cr3 Cr
Tax %0.0%0.0%-10.5%-0.5%0.0%0.0%-0.2%0.0%0.0%0.0%0.0%2.2%
Net profit20 Cr29 Cr33 Cr29 Cr27 Cr21 Cr22 Cr15 Cr-6 Cr-13 Cr24 Cr3 Cr
EPS (₹)₹4.30₹6.18₹6.81₹5.79₹5.37₹4.10₹4.40₹2.94₹-1.13₹-2.49₹4.69₹0.54

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales797 Cr688 Cr600 Cr508 Cr450 Cr560 Cr666 Cr819 Cr922 Cr811 CrSign in free for the trailing twelve months
Operating expenses (approx.)709 Cr672 Cr618 Cr534 Cr400 Cr510 Cr582 Cr709 Cr805 Cr770 CrSign in free for the trailing twelve months
EBITDA87 Cr16 Cr-18 Cr-25 Cr50 Cr50 Cr84 Cr111 Cr117 Cr41 CrSign in free for the trailing twelve months
OPM %10.9%2.3%-3.0%-5.0%11.1%8.9%12.6%13.5%12.7%5.1%Sign in free for the trailing twelve months
Other income19 Cr20 Cr17 Cr24 Cr15 Cr9 Cr19 Cr31 Cr27 Cr35 CrSign in free for the trailing twelve months
Interest331 Cr302 Cr0.30 Cr4 Cr51 Cr32 Cr32 Cr16 Cr15 Cr13 CrSign in free for the trailing twelve months
Depreciation141 Cr133 Cr130 Cr126 Cr109 Cr87 Cr55 Cr33 Cr35 Cr35 CrSign in free for the trailing twelve months
Profit before tax-539 Cr-399 Cr69 Cr-131 Cr-117 Cr-2 Cr46 Cr89 Cr99 Cr20 CrSign in free for the trailing twelve months
Tax %8.9%11.6%0.0%0.0%0.0%0.0%0.0%-3.5%-0.2%-0.9%Sign in free for the trailing twelve months
Net profit-490 Cr-353 Cr69 Cr-131 Cr-117 Cr-2 Cr46 Cr92 Cr100 Cr21 CrSign in free for the trailing twelve months
EPS (₹)₹-55.13₹-39.65₹7.80₹-32.11₹-28.55₹-0.48₹11.35₹19.06₹19.65₹4.05Sign in free for the trailing twelve months
Dividend payout %——————0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital89 Cr89 Cr89 Cr41 Cr41 Cr41 Cr41 Cr51 Cr51 Cr51 Cr
Reserves-477 Cr-881 Cr-793 Cr984 Cr612 Cr607 Cr648 Cr1,119 Cr1,217 Cr1,237 Cr
Borrowings2,756 Cr2,588 Cr2,120 Cr501 Cr430 Cr268 Cr331 Cr134 Cr174 Cr357 Cr
Other liabilities989 Cr1,329 Cr1,661 Cr196 Cr154 Cr195 Cr205 Cr250 Cr246 Cr266 Cr
Total liabilities3,358 Cr3,125 Cr3,077 Cr1,722 Cr1,237 Cr1,111 Cr1,225 Cr1,554 Cr1,688 Cr1,911 Cr
Fixed assets (net)1,376 Cr1,268 Cr1,141 Cr1,021 Cr670 Cr583 Cr573 Cr619 Cr632 Cr613 Cr
CWIP274 Cr257 Cr264 Cr78 Cr7 Cr10 Cr46 Cr16 Cr64 Cr341 Cr
Investments0.96 Cr1 Cr0.47 Cr0.34 Cr15 Cr45 Cr44 Cr46 Cr50 Cr53 Cr
Inventories211 Cr194 Cr170 Cr156 Cr153 Cr173 Cr229 Cr264 Cr326 Cr256 Cr
Trade receivables203 Cr120 Cr120 Cr68 Cr136 Cr171 Cr215 Cr196 Cr242 Cr264 Cr
Cash & bank257 Cr35 Cr92 Cr90 Cr16 Cr4 Cr23 Cr4 Cr21 Cr7 Cr
Other assets1,036 Cr1,250 Cr1,290 Cr309 Cr240 Cr124 Cr95 Cr409 Cr353 Cr377 Cr
Total assets3,358 Cr3,125 Cr3,077 Cr1,722 Cr1,237 Cr1,111 Cr1,225 Cr1,554 Cr1,688 Cr1,911 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity317 Cr9 Cr12 Cr81 Cr29 Cr89 Cr19 Cr126 Cr19 Cr101 Cr
Cash from investing-9 Cr-28 Cr45 Cr167 Cr95 Cr116 Cr-31 Cr-312 Cr-27 Cr-285 Cr
Cash from financing-366 Cr33 Cr-0.30 Cr-250 Cr85 Cr-217 Cr31 Cr167 Cr25 Cr170 Cr
Net cash flow-58 Cr15 Cr57 Cr-2 Cr209 Cr-11 Cr18 Cr-19 Cr18 Cr-14 Cr
Free cash flow (OCF − Capex)308 Cr3 Cr5 Cr77 Cr29 Cr75 Cr-66 Cr126 Cr-131 Cr-282 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %—-6.5%-10.5%-8.3%-6.0%3.3%7.7%8.1%7.9%2.0%
ROE %———-12.8%-17.8%-0.3%6.7%7.9%7.9%1.6%
Debtor days936373491101111188795118
Inventory days226207235241227185205183203202
Days payable453383419160163179163159138181
Cash conversion cycle-135-113-111130173116160111160139
OCF / EBITDA %363.8%n.m.——58.1%179.3%22.2%113.8%16.4%246.0%
OCF / EBITDA % (3 years)——399.7%—n.m.268.8%74.6%95.7%52.6%91.6%
Debt / equity—0.000.000.490.660.410.480.110.140.28
Current ratio0.570.340.303.253.021.811.353.042.832.45
Net debt / EBITDA28.68162.67——8.335.313.691.181.318.52